UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Regression of a melanoma brain metastasis that had appeared after immune checkpoint inhibitor discontinuation: a hypothesis-generating case

Acta clinica belgica (English ed. Online), 2023-12, Vol.78 (6), p.516-520

2023

Volltextzugriff (PDF)

Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer

International journal of women's health, 2014-01, Vol.6 (default), p.351-358

2014

Volltextzugriff (PDF)

Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?

Annual review of cancer biology, 2020-03, Vol.4 (1), p.241-256

2020

Volltextzugriff (PDF)

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Clinical cancer research, 2022-06, Vol.28 (12), p.2527-2535

2022

Volltextzugriff (PDF)

Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks

JAAD international, 2023-03, Vol.10, p.31-33

2023

Volltextzugriff (PDF)

HOXA1 Is an Antagonist of ERα in Breast Cancer

Frontiers in oncology, 2021-08, Vol.11, p.609521-609521

2021

Volltextzugriff (PDF)

Centralizing surgery for ovarian cancer in a ‘non-centralizing’ country (Belgium): the UNGO (UCLouvain Network of Gynaecological Oncology) experience

International journal of gynecological cancer, 2023-10, Vol.34 (1), p.106-112

2023

Volltextzugriff (PDF)

Hyperpolarized 13C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts

International journal of molecular sciences, 2023-01, Vol.24 (3), p.2499

2023

Volltextzugriff (PDF)

Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature

Frontiers in medicine, 2018-08, Vol.5, p.240-240

2018

Volltextzugriff (PDF)

Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.6050-6050

2020

Volltextzugriff (PDF)

Hysteroscopic management of molar pregnancy: A series of 36 cases

Rare tumors, 2023-03, Vol.15, p.20363613231168767-20363613231168767

2023

Volltextzugriff (PDF)

Intraoperative Ketorolac and Outcomes after Ovarian Cancer Surgery

Journal of clinical medicine, 2024-03, Vol.13 (6), p.1546

2024

Volltextzugriff (PDF)

Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial

Journal of clinical oncology, 2016-06, Vol.34 (18_suppl), p.LBA2000-LBA2000

2016

Volltextzugriff (PDF)

Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy

Proceedings of the National Academy of Sciences - PNAS, 2014-03, Vol.111 (9), p.3502-3507

2014

Volltextzugriff (PDF)

391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A237-A238

2020

Volltextzugriff (PDF)

A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients

Dermatology Research and Practice, 2012-01, Vol.2012 (2012), p.80-86

2012

Volltextzugriff (PDF)

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A260-A261

2020

Volltextzugriff (PDF)

Correction: Tamoxifen and Ovarian Function

PloS one, 2013-10, Vol.8 (10)

2013

Volltextzugriff (PDF)

Lymphoid neogenesis in melanoma: What does it tell us?

Oncoimmunology, 2013-01, Vol.2 (1), p.e22505-e22505

2013

Volltextzugriff (PDF)

Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

Clinical therapeutics, 2024-08, Vol.46 (8), p.612-621

2024

Volltextzugriff (PDF)

Metabolic imaging using hyperpolarized 13C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts

Journal of cellular and molecular medicine, 2020-01, Vol.24 (2), p.1934-1944

2020

Volltextzugriff (PDF)

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic

ESMO open, 2018, Vol.3 (5), p.e000384-e000384, Article e000384

2018

Volltextzugriff (PDF)

A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

Future oncology (London, England), 2024-04, Vol.20 (13), p.799-809

2024

Volltextzugriff (PDF)

Corrigendum to “Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy” [Eur J Cancer 67 (2016) 38–45]

European journal of cancer (1990), 2017-09, Vol.82, p.247-247

2017

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(72)
Berichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Regression of a melanoma brain metastasis that had appeared after immune checkpoint inhibitor discontinuation: a hypothesis-generating case

Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer

Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

HOXA1 Is an Antagonist of ERα in Breast Cancer

Centralizing surgery for ovarian cancer in a ‘non-centralizing’ country (Belgium): the UNGO (UCLouvain Network of Gynaecological Oncology) experience

Hyperpolarized 13C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts

Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature

Evaluation of an individualized starting-dose of niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study

Hysteroscopic management of molar pregnancy: A series of 36 cases

Intraoperative Ketorolac and Outcomes after Ovarian Cancer Surgery

Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial

Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy

391 A first-in-human study of intratumoral SAR441000, an mRNA mixture encoding IL-12sc, interferon alpha2b, GM-CSF and IL-15sushi as monotherapy and in combination with cemiplimab in advanced solid tumors

A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients

428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs)

Correction: Tamoxifen and Ovarian Function

Lymphoid neogenesis in melanoma: What does it tell us?

Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer

Metabolic imaging using hyperpolarized 13C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic

A plain language summary of publication of the efficacy and safety of individualized niraparib dosing based on baseline body weight and platelet count in the PRIMA/ENGOT-OV26/GOG-3012 trial

Corrigendum to “Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy” [Eur J Cancer 67 (2016) 38–45]

Aktive Filter

Suchergebnisse filtern